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Abstract 
Objectives To compare the prevalence of silent cerebral ischemia (SCI) and cognitive 
performance in paroxysmal and persistent atrial fibrillation (AF) patients and controls in Sinus 
Rhythm (SR).  
Background Large registries reported a similar risk for symptomatic stroke in both paroxysmal 
and persistent AF. The relationship between paroxysmal and persistent AF, SCI and cognitive 
impairment has remained uncharted.  
Methods and results Two hundred-seventy subjects were enrolled: 180 patients with AF (50% 
paroxysmal and 50% persistent) and 90 controls. All subjects received clinical assessment, 
neurological examination, cerebral magnetic resonance (MR) and underwent the Repeatable 
Battery for the Assessment of Neuropsychological Status (RBANS). At least one SCI was 
present in 80 (89%) patients with paroxysmal, 83 (92%) with persistent AF (paroxysmal vs 
persistent; p=0.59) and in 41 (46%) controls (paroxysmal vs controls and  persistent vs controls; 
p<0.01). Number of SCI per person was higher in persistent than in paroxysmal AF patients 
(41.1±28.0 vs 33.2 ±22.8; p=0.04), with controls reporting lower figures (12.0±26.7; both 
p<0.01).  Cognitive performance was significantly worse in persistent and paroxysmal AF 
patients than in controls (RBANS 82.9±11.5, 86.2±13.8 and 92.4±15.4 points respectively; 
p<0.01).   
Conclusions Paroxysmal and persistent AF patients presented a higher prevalence and number 
of SCI per patient than controls and confirmed a worse cognitive performance than subjects in 
SR.  
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Introduction 
Atrial fibrillation (AF) is known to relate, independently from the presence of other 
comorbidities, to enhanced mortality and thromboembolism (1), particularly to the brain. To date 
large registries have reported a similar risk for symptomatic stroke in both the paroxysmal and 
the persistent form of this arrhythmia (2–4). A recent clinical experience on patients with acute 
cerebral infarction suggested, however, that patients with persistent AF present a significantly 
worse short-term outcome both in functional ability and survival respect to those with 
paroxysmal AF (5).  
If symptomatic brain damage is easily diagnosed, the relationship between AF, both paroxysmal 
and persistent, and silent cerebral ischemia (SCI) has remained uncharted. The presence of SCI is 
of relevant interest as it was associated to increased occurrence of stroke (6) and development of 
cognitive impairment (7, 8). 
Few studies (9–13) have, in fact, investigated the prevalence of SCI in patients with AF. The 
limited sample size, the retrospective design, or the heterogeneity of patients and techniques (e.g. 
computed tomography, CT vs magnetic resonance, MR) involved in these studies explain the 
broad variations reported from 15% to 86%. In addition the relationship between paroxysmal and 
persistent AF and cognitive decline has, to date, relied only on clinical data, not supported by 
cerebral imaging (14–17).  
Aims of the present study are to compare: 1) prevalence of SCI and 2) cognitive performance in 
paroxysmal and persistent non valvular AF patients and in controls in sinus rhythm (SR), without 
history of AF. 
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Methods 
Study population  
From November 2008 to September 2012 consecutive patients referred to our Cardiology 
Division or Cardiovascular Prevention Outpatient Clinic were screened to generate three age, 
gender, risk factors and education level-balanced groups of patients with paroxysmal or 
persistent AF or without history of AF.  
Exclusion criteria were: valvular heart disease, acute coronary syndrome less than 3 months 
before, previous transcatheter ablation, pace-maker implantation or other MR contraindications, 
history of transient ischemic attack (TIA) or stroke, autoimmune diseases, inflammatory brain 
diseases, tumors, severe hepatic disorders, severe chronic renal insufficiency and alcohol abuse.  
All patients were screened by the Mini Mental State Evaluation (MMSE) (18) and the Beck 
Depression Inventory (BDI) scale (19) to rule out dementia or depression. Participants with 
scores ≤ 24 points on the MMSE and ≥ 10 on the BDI were excluded.  
Flow chart reporting numbers and reasons of exclusion of the screened cohort down to the final 
study population is reported in Figure 1.  
The final study population enrolled 270 subjects: 180 patients with AF, 90 paroxysmal and 90 
persistent and 90 controls in SR without history of AF. AF was defined paroxysmal if self-
terminating within 7 days and persistent if at least one AF episode lasted longer than 7 days, 
based on direct patient interview and/or exhaustive medical papers search. 
All patients gave written informed consent before enrolment; the study was conducted in 
accordance to the latest Declaration of Helsinki and approved by the Local Ethical Committee. 
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Baseline evaluation 
All screened subjects underwent extensive clinical assessment, including: medical history 
(targeted to AF type and duration, presence of heart disease, comorbidities), thromboembolic 
risk assessment (CHA2DS2-Vasc score, congestive heart failure/left ventricular dysfunction; 
hypertension; age; diabetes; stroke/transitory ischemic attack, thromboembolism; vascular 
disease) (20), physical examination and electrocardiogram. Hypertension was defined as blood 
pressure ≥140/90 mmHg (grade 1 hypertension: 140-159/90-99 mmHg, grade 2 hypertension 
160-179/100-109 (21). Diabetes was defined as HbA1c ≥ 6.5% (22). Hypercholesterolemia was 
considered in case of evidence of a total cholesterol blood sample above 240 mg/dl (23). 
Smoking was considered habitual if the patient smoked at least 20 cigarettes a day for at least 1 
year.  
A standardized neurological examination, according to the National Institute of Health Stroke 
Scale, was performed by a certified neurologist. In addition, all patients underwent Echo-
Doppler sonography to exclude carotid and vertebro-basilar district morphological and/or 
functional damage (stenosis of the lumen ≥70%, according to European Carotid Surgery Trial 
criteria or a peak systolic flow velocity > 150 cm/sec).  
 
Cognitive performance 
Cognitive function was assessed by a certified neuropsychologist with the Repeatable Battery for 
the Assessment of Neuropsychological Status (RBANS) (24, 25) exploring 5 domains: 
immediate memory, visual-spatial abilities, language, attention and delayed memory. 
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Magnetic resonance imaging 
Cerebral images were obtained with an 8-channel head coil 1.5 Tesla MR imaging system 
(Magneton Avanto®, Siemens, Erlangen, Germany). The imaging protocol included: a sagittal 
T1-weighted spin echo sequence (repetition time/echo time 400/13; slice thickness 5 mm; field 
of view 230 mm; matrix 192x256), an axial T2 fluid-attenuated inversion recovery (T2 FLAIR) 
weighted sequence (repetition time/echo time 8500/112; TI 2500 ms; slice thickness 5 mm; field 
of view 240 mm; matrix 154x256; seconds) and a diffusion-weighted (DW) sequence (repetition 
time/echo time 3200/99; slice thickness 5 mm; field of view 230 mm; matrix 128%128; 
bandwidth 1502 Hz; gradient strength 22 mT; duration of diffusion gradients 31 ms; gradient 
separation 42 ms in 3 orthogonal directions, B value 1000). For each DW sequence, the apparent 
diffusion coefficient map was obtained. All sequences were centered on the axis defined by a 
line passing between the anterior and posterior cerebral commissures.  
According to anatomo-pathological criteria (26), SCI were defined as focal, sharply demarcated, 
regularly or irregularly shaped areas hyperintense on T2 FLAIR or isointense in T1 weighted 
images. T2 FLAIR were used to differentiate gliotic ischemic lesions smaller than 3 mm from 
perivascular spaces and lacunes (hypointense on T2 FLAIR weighted images) (27).  
The presence of even only one lesion allocated the subject within the SCI group. Each individual 
SCI was recorded and small lesions closely grouped together, exclusively localized in the 
subcortical white matter of the frontal lobe, were defined as “spotted pattern”. 
All MR scans were independently analyzed by two neuroradiologists, blinded to clinical data; 
conflict was resolved by common agreement referring to a third expert. 
7 
Statistical analysis 
Continuous variables, presented as means and standard deviations (SD), were compared by 
analysis of variance (ANOVA) and subgroup comparisons corrected by the post-hoc 
Bonferroni’s correction. Categorical variables, presented as counts and percentages, were 
compared in cross tabulation tables by chi square test (Yates’s correction, as appropriate) and 
Odds Ratio (OR) with their 95% confidence intervals (95% CI) computed. A logistic regression 
model was performed to determine the correlation between SCI and potential confounders 
selected at univariate analysis (p<0.5). All analyses were performed by the SPSS package for 
Windows (v. 18.0, SPSS Inc, Chicago, IL, USA) and a p value below 0.05 was considered as 
statistically significant. 
 
Results 
Baseline characteristics of the final patient population are summarized in Table 1. 
 
Silent cerebral ischemia 
At least one SCI was present in 80 (89%) patients with paroxysmal AF, 83 (92%) with persistent 
AF (paroxysmal vs persistent AF; p = 0.59) and in 41 (46%) controls (paroxysmal vs controls 
and persistent vs controls; p < 0.01).  
Cerebral lesions were bilateral in 81 (90%) persistent and 80 (89%) paroxysmal AF patients (p = 
1) compared to 36 (40%) within controls (paroxysmal vs controls and persistent vs controls; both 
p<0.01). SCI were cortical and subcortical in 75 (83%) and 77 (85%) paroxysmal AF patients, in 
79 (88%) and 82 (91%) persistent AF patients and in 19 (21%) and 44 (49%) within controls, 
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respectively (paroxysmal vs persistent AF; p = 0.5 and p = 0.35; AF patients vs. controls; p < 
0.01). 
The number of SCI per person was significantly higher in persistent than in paroxysmal AF 
patients (41.1 ± 28.0 vs 33.2  ± 22.8; p = 0.04). The number of SCI per person was significantly 
higher in paroxysmal and in persistent AF patients than in controls, reporting lower figures (12.0 
± 26.7; paroxysmal vs controls and persistent vs controls; both p < 0.01). AF showed a higher 
risk for SCI respect to subjects in SR [OR, Odds Ratio = 11.2 (6-21); p < 0.01] whereas no 
difference was found between the two different forms of the arrhythmia [OR=1.5 (0.5-4.1); p = 
0.61]. At multivariate analysis, adjusted for age, CHA2DS2-Vasc score and  antiplatelet/oral 
anticoagulation treatment, the presence of AF was strongly independently related to the presence 
of SCI (OR 7.2, 95%CI 2,3-22,3; p=0.001).   
The prevalence of “spotted pattern” in the frontal lobe was more represented in persistent than in 
paroxysmal AF (67% vs 50%; p = 0.03). In controls the presence of this patterns was negligible 
(1%).  
 
Cognitive function 
Cognitive performance, assessed by RBANS, was significantly worse in persistent and 
paroxysmal AF patients than in controls: 82.9 ± 11.5, 86.2 ± 13.8, and 92.4 ± 15.4 points, 
respectively (paroxysmal vs persistent AF; p = 0.08; paroxysmal and persistent AF vs controls; p 
< 0.01). In details, AF patients obtained lower mean scores than controls in all the explored 
domains: immediate memory, visual-spatial abilities, language, attention and delayed memory 
(Figure 2). Concerning AF type, persistent AF patients presented a trend toward lower RBANS 
scores mainly driven by significantly worse visual-spatial abilities (84.8 ± 14.8 vs 89.9 ± 18.2; p 
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= 0.04) compared to patients with the paroxysmal form of the arrhythmia.  
Among AF patients, those with the frontal pattern (58%) presented a trend toward a lower mean 
total score compared to those without (82.9 ± 12.0 vs 86.5 ± 15; p = 0.06). However, they scored 
significantly lower in visual-spatial ability subtest respect to subjects without this pattern (85.1 ± 
16.7 vs 90.7 ± 17; p = 0.02).  
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Discussion 
The present is, to the best of our knowledge, the first study investigating the relationship between 
AF and cognitive decline supported by specifically addressed cerebral MR imaging. 
The major findings of this study are:  
1) AF patients (both paroxysmal and persistent) present higher prevalence but, most of all, 
number of SCI per person compared to controls; 
2) persistent relates to higher SCI per person compared to paroxysmal AF; 
3) AF patients have a worse cognitive performance compared to controls; 
4) despite similar cognitive function by RBANS between paroxysmal and persistent AF 
patients, visual-spatial abilities were worse in persistent AF. 
The incidence of clinical ischemic stroke has been reported as up to five-fold higher in AF 
patients compared to the general population (2, 3, 28). Similarly the present study including 
subjects with homogenous cardiovascular risk factors by study design reported a higher risk of 
SCI in AF patients compared to subjects in SR.  
The high prevalence of SCI within controls (46%), compared to that reported in the general 
population (29, 30), may relate to the baseline characteristics of this group. Due to their selection 
within patients referring to a Cardiovascular Prevention Outpatient Clinic, the control group 
presented a moderate to high cardiovascular risk profile. Interestingly, the prevalence of SCI in 
subjects with similar cardiovascular risk profile in previous experiences ranges from 53 to 58%, 
similar to that reported in the present study (12, 13, 31). 
Besides the higher prevalence of SCI, by discriminating individual lesions in each patient, we 
registered a higher number of SCI per person in paroxysmal and persistent AF patients compared 
to controls.  
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SCI may certainly have both ischemic and embolic origin. The design of the study, comparing 
AF patients and non-AF controls with similar prevalence of classical cardiovascular factors 
should, however, permit to focus on the excess due to AF related embolic lesions. Emboli of 
cardiac origin are generally smaller than those due to atherothrombotic material and cause 
lesions widely distributed, on both sides, of the brain (9, 32, 33). On the contrary, emboli, for 
instance of carotid artery origin, are usually larger in size and damage the ipsilateral hemisphere. 
For these reasons the peculiar cerebral MR pattern described in 50% and 67% of the paroxysmal 
and persistent AF patients, respectively presenting small sharply demarcated lesions, often in 
cluster, with bilateral distribution, prevalently in the frontal lobe strongly supports an embolic 
mechanisms. This pattern is, in fact, clearly distinguishable from an atherosclerotic damage 
ipsilateral to a vascular lesion. In our opinion, the “spotted pattern” described in this study may 
derive from microembolization of multiple small platelet thrombi in the terminal brain vessels 
(especially the leptomeningeal arteries)”. 
Furthermore, although patients with paroxysmal and persistent AF did not present differences in 
SCI prevalence, persistent AF showed a higher number of lesions. To date, persistent and 
paroxysmal AF were considered to present similar stroke risk (2–4) and studies on symptomatic 
cerebral damage rarely differentiate between the two clinical forms of the arrhythmia.  
This result might be related to the longer presence and duration of AF in the persistent form 
causing a greater exposure time to AF related thromboembolic etiology. Considering the high 
clinical impact that this finding may provide it surely warrants further confirmation. 
As shown in Table 1 paroxysmal were more commonly prescribed antiaggregant therapy 
compared to persistent AF patients. This somewhat surprising finding most likely is due to the 
fact that patients were enrolled between 2008 and 2012. The evidence that aspirin is not 
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beneficial in AF patients first emerged in 2011 (34). Before this date aspirin was commonly, 
although not evidence-based, chosen for treatment of patients with paroxysmal episodes. 
As suggested by previous researches (16, 17) AF relates to cognitive decline; in particular 
Santangeli et al. outlined that AF independently increases the risk of incident dementia both in 
elderly patients without acute stroke and with normal baseline cognitive function. 
AF patients performed worse in all investigated cognitive domains compared to subjects without 
history of AF.  Interestingly the score difference highlighted between AF patients and controls 
relates to a relevant clinical shift from a medium to a medium-low cognitive performance (24).  
Overall in our dataset RBANS score and number of SCI were poorly related (Pearson correlation 
coefficient  r=0.185; p=0.02). In our opinion this has two main explanations. First, the loss of 
neuropsychological and cognitive function deriving from a cerebral lesion depends on its 
localization and dimension. Differences in cognitive function seem more related to the presence 
of small clustered lesions in the subcortical frontal region than to the overall number of SCI. 
Patients with the frontal pattern (58%) presented a clear trend toward lower total scores (82.9 
±12.0 vs. 86.5 ±15; p = 0.06) and, especially, they scored significantly lower in the visual- 
spatial ability subtests (85.1 ±16.7 vs. 90.7 ±17; p = 0.02) compared to subjects without this 
pattern. In fact, the frontal subcortical cerebral circuits (35) which could indeed be damaged by 
the presence, at this level, of the “spotted pattern” are involved in several neurological activities 
such as visual spatial abilities.  Second, the neuropsychological test used in the present study is a 
first level assessment tool, exploring only a limited selection of cognitive functions. We 
therefore cannot exclude that the cognitive measures used may in certain cases perform above 
the detection threshold.  
Finally, the anatomical brain damage visible by MR did not remain, from a functional point of 
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view, really "silent". The present data suggest that an initially limited cerebral damage may 
become overt as the number of cerebral lesions increases due to persistence of the arrhythmia. 
 
Study limitations 
In addition to those reported above the following general limitations apply to this study. The 
cross sectional study design investigating time dependent risks may represent a source of bias. 
Future research on this topic should hopefully include longitudinal studies with appropriate 
power and sample size. Furthermore, as in most studies on this topic, an accurate measurement 
of the effective period of anticoagulation or antiaggregant therapy during exposure to the 
arrhythmia is lacking. For these reasons the results of the present study are to be considered as 
suggestive, and not conclusive, for further research on this clinically relevant topic. 
 
Conclusions 
As for symptomatic strokes, AF patients, both paroxysmal and persistent, suffer higher 
prevalence of AF related silent cerebral ischemia compared to controls in SR. Finally AF 
patients were confirmed to have a worse cognitive performance than subjects in SR. 
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Table 1. Baseline characteristics of atrial fibrillation patients and controls included in the final 
study population. Values reported as counts and percentage if not differently stated.  
 
Variable 
Paroxysmal AF 
 (n = 90) 
Persistent AF 
 (n = 90) 
Controls 
 (n = 90) 
p Value 
Age (years) 58.6 ± 10.2 61.2 ± 10.9 59.7± 13.1 0.31  
Gender (male) 69 (76.7%) 72 (80%) 68 (75.6%) 0.76 
Hypertension 46 (51.1%) 47 (52.2%) 45 (50%) 0.96 
   grade 1  33 (36.7%) 28 (31.1%) 33 (36.7%) 0.66 
   grade 2 13 (14.4%) 19 (21.1%) 12 (13.3%) 0.31 
   on drugs 39 (43.3%) 41 (45.6%) 36 (40%) 0.75 
B-Blockers 33 (36.7%) 36 (40%) 27 (30%) 0.36 
ACEis*/ARBs† 28 (31.1%) 28 (31.1%) 25 (27.8%) 0.85 
Diabetes 5 (5.6%) 7 (7.8%)  5 (5.6%) 0.78 
Heart disease: 6 (6.7%) 9 (10%)   7 (7.8%) 0.71 
   coronary artery disease 3 (3.3%) 3 (3.3%)  4 (4.4%) 0.90 
   hypertrophic cardiomyopathy 1 (1.1%) 2 (2.2%)  1 (1.1%) 0.78 
   ipokinetic cardiomyopathy 1 (1.1%) 3 (3.3%)  2 (2.2%) 0.60 
   congenital heart disease 1 (1.1 %) 1 (1.1%)  0 (0%) 0.60 
AF duration (months) 84.2±70.4 85.2±91.2 - 0.80 
Time since persistent AF (months) - 15±28 -  
CHA2DS2-Vasc‡     
   0 27 (30%) 24 (26.7%) - 0.74 
20 
 
* ACEis, Angiotensin-converting enzyme inhibitors. 
† ARBs, Angiotensin receptor blockers. 
‡ CHA2DS2-Vasc, congestive heart failure/left ventricular dysfunction; hypertension; age; 
diabetes; stroke/transitory ischemic attack, thromboembolism; vascular disease. 
§ Education level: 1,  up to 5 school years;  2, up to 8 years; 3, up to 13 years; 4, above 13 years. 
║OAC, oral anticoagulation.   
 
 
 
 
 
 
   1 34 (37.8%) 24 (26.7%) - 0.15 
   2 19 (21.1%) 22 (24.4%) - 0.72 
   > 2 10 (11.1%) 20 (22.2%) - 0.07 
Dyslipidemia 26 (28.9%) 21 (23.3%) 24 (26.7%) 0.69 
Antiplatelets/OAC║      
   OAC 39 (43.3%) 79 (87.8%) 0 (0%) < 0.01 
   Aspirin 100 mg/day 34 (37.8%) 9 (10%) 11 (12.2%) < 0.01 
   None 17 (18.9%) 2 (2.2%) 79 (87.8%) < 0.01 
Smoking habit 26 (28.9%) 26 (28.9%) 31 (34.4%) 0.65 
Education level§ 2.6±0.9 2.6±0.9  2.5 ±1.0 0.71 
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Figure 1: Flow chart reporting numbers and reasons of exclusion of the screened cohort down to 
the final study population.  
 
 
 
AF, atrial fibrillation; MR, magnetic resonance; RBANS, Repeatable Battery for Assessment of 
Neuropsychological status;  TIA, transitory ischemic attack.  
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Figure 2: Cognitive function by Repeatable Battery for Assessment of Neuropsychological 
Status (RBANS) score in controls (triangles), Paroxysmal (PRX, diamonds) and Persistent (PER, 
squares)  AF patients.  
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Figure 3: 55 years-old male with paroxysmal atrial fibrillation without other risk factors: axial 
FLAIR images demonstrate multiple small hyperintense lesions at the subcortical level in both 
hemispheres. Clusters (arrows) of small lesions are visible in the left frontal and temporo-parietal 
regions (A), in the left frontal (B) and in the right frontal lobe (C). 
 
 
 
